Middle East & Africa Lyme Disease Diagnostic Market

Middle East & Africa Lyme Disease Diagnostic Market Size & Growth (2023 to 2028)

As Per the Report, the Size of the MEA Lyme Disease Diagnostic Market is valued at USD xx Million in 2023 and is expected to grow at a CAGR of XX.X%, reaching USD XX Million by 2028 during the forecast period 2023 to 2028.

The growing awareness of novel approaches for diagnosing Lyme disease and recognizing chronic Lyme infection from a blood sample drives the MEA Lyme disease diagnostics industry.

These tests' availability will help address the issue of assay accuracy plaguing serology-based assays. The spread of Lyme disease will likely fuel the target market's growth. In addition, the Lyme disease diagnostics market's growth potential is predicted to be boosted by market participants' research and development initiatives.

Furthermore, government attempts to modernize medical healthcare facilities are expected to boost market expansion in the upcoming years. In addition, the rising number of tick-borne infectious diseases, the incidence of novel forms of vector-borne diseases, & rising healthcare spending are expected to drive the MEA Lyme disease diagnostics market even higher. 

The National Institute of Allergy and Infectious Diseases supports the development of new techniques to improve Lyme disease screening in collaboration with the Centers for Disease Control and Prevention (CDC). Furthermore, the National Institute of Allergy and Infectious Diseases grantees work closely with the Centers for Disease Control and Prevention (CDC). 

Leading market companies are working on new Lyme disease diagnostic tests, which will help the MEA Lyme disease diagnostics market grow. Because current serological techniques cannot consistently detect antibodies to all borrelia burgdorferi strains, many people with Lyme-like symptoms are misdiagnosed. As a result, there is an increasing demand for better disease diagnostic tests.

The growth of the MEA Lyme disease diagnostics market is hampered by a lack of public awareness about the disease and poor Lyme disease testing in developing and emerging markets. Furthermore, the Lyme disease diagnostics industry has stagnated over time due to a lack of Lyme disease therapy in rural areas. In addition, Lyme disease diagnosis was postponed in the spring of 2020 due to COVID-19 pandemic-related changes in healthcare workflow and diagnostic rationale.

This research report on the Middle East & Africa Lyme Disease Diagnostic Market has been segmented and sub-segmented into the following categories.

By Darkfield microscopy:

• Urine antigen tests
• lymphocytic transformation test
• Serological tests
• immunofluorescence staining
• PCR tests

By Diagnostic Technologies:

• Molecular diagnostics
• Monoclonal antibodies
• Flow cytometry
• Brain MRI
• Spinal tap
• Echocardiogram
• Electrocardiogram
• Micro droplets

By End User:

• hospitals/clinics
• Pharmaceutical Industries
• Pathology labs
• Research Institutes

By Country:

• KSA
• UAE
• Israel
• the rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, the MEA Lyme disease diagnostic market is expected to develop at a stable rate during the projected period owing to the rising frequency of Lyme disease. Government support to establish healthcare facilities are expected to drive the market's growth at this rate. Several research institutes and organizations operate the MEA Lyme disease diagnostics market, and healthcare firms are working to develop better technology for detecting Lyme disease.

The UAE Lyme disease diagnostic market is predicted to rise at a decent rate due to the rising number of tick-borne disease cases is boosting the market in this region.

The Saudi Arabia Lyme disease diagnostic market is expected to dominate the MEA Lyme disease diagnostic market because government activities are expanding and healthcare expenditures are increasing, among other reasons which drive the market expansion.

The Kuwait Lyme disease diagnostic market is predicted to hold the most significant market share. A well-established healthcare infrastructure also contributes significantly to the total regional market's growth.

The South African Lyme disease diagnostic market is estimated to develop significantly during the predicted period. In addition, metabolic biomarkers and biosignatures are being identified and characterized for improved diagnoses. All of this research is likely to contribute to new techniques for detecting Lyme disease, as well as earlier diagnosis, accurate disease staging, and signs of successful therapy.

KEY MARKET PLAYERS

Key Market Companies leading the Middle East & Africa Lyme Disease Diagnostics Market Profiled in the Report are Baxter International Inc, Fresenius Medical Care AG & Co, Boulder Diagnostics, Immunetics Inc, Graphene Frontiers, Covance Inc, Affymetrix Inc, Siemens AG, Bio-Rad Laboratories, Alere Inc (ALR), Roche Diagnostics International Ltd, GlaxoSmithKline Pharmaceuticals Ltd, .,